Advocates launch campaign to shift peptide manufacturing to the US

Biotech accelerator organizers hosted a gathering on the SS Jeremiah O’Brien to advocate for bringing the pharmaceutical supply chain for peptides back to the United States. Around 150 attendees sampled topical and sublingual peptide products while discussing the need for American-made alternatives. The push for domestic manufacturing comes amid controversy surrounding the US Department of Health and Human Services' interim policy decision permitting certain unapproved peptides for compounding. While industry players and telehealth brands debate the regulatory and safety implications of these gray-market products, advocates are doubling down on local production.